A new $500 million fund backed by Stripe, Anthropic and others will support drugs and air filtration tech aimed at preventing colds, flu and other respiratory viruses. It plans to shepherd at least two therapies through Phase I/II trials and pilot air-cleaning systems in offices to de-risk them for larger investors.

The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

Science Corp, led by Max Hodak, will test its biohybrid brain sensor in humans under Dr. Murat Günel’s guidance. The implant, which sits on the cortex inside the skull and uses 520 electrodes, will first be tried without neurons in patients already undergoing craniotomy. The long-term goal is to integrate lab-grown neurons with electronics to treat stroke, spinal injuries and Parkinson’s.

The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.

The FDA plans to allow drug approvals based on a single clinical trial instead of the traditional two. Commissioner Marty Makary stated that this change aims to streamline the approval process while maintaining safety and efficacy standards. Some exceptions will still apply, where two trials may be required.

Claude for Healthcare is now available, providing HIPAA-compliant tools for healthcare providers and patients to improve medical processes such as prior authorizations and claims appeals. Additionally, Claude for Life Sciences has expanded its capabilities to better support clinical trial operations and regulatory submissions. These advancements aim to streamline healthcare tasks and enhance the quality of patient care.

Biomedical progress in therapeutics has been hindered despite advances in basic science, a trend known as Eroom's Law. The Clinical Trial Abundance Project aims to enhance the efficiency and informativeness of clinical trials, arguing that learning from both successes and failures is crucial for developing new therapies, as exemplified by the evolution of CAR-T cell therapies.